Octapharma AG, established in 1983 and headquartered in Lachen, Switzerland, is a privately-owned pharmaceutical company specializing in the development and production of human proteins derived from human plasma and cell lines. The company operates across three primary therapeutic areas: Immunotherapy, Hematology, and Critical Care.
Company Overview
- Foundation and Ownership: Founded by Wolfgang Marguerre, Octapharma remains a family-owned enterprise, with Marguerre serving as Chairman and CEO.
- Global Presence: The company employs over 11,000 individuals worldwide and treats patients in 118 countries. It operates seven R&D sites and five manufacturing facilities located in Austria, France, Germany, and Sweden. Additionally, Octapharma manages more than 190 plasma donation centers across Europe and the United States.
Financial Performance
Octapharma has demonstrated consistent financial growth over recent years:
- 2024: Sales increased by 6.1% to €3.466 billion, with an operating income of €532 million, marking a 21.9% rise from the previous year.
- 2023: The company reported a 14.4% increase in sales, reaching €3.266 billion, and an operating income of €436 million.
- 2022: Sales grew by 13.7% to €2.854 billion, with an operating income of €522 million.
Product Portfolio
Octapharma's product offerings address a range of medical conditions:
- Hematology: Products like octanate®, octanine-F®, wilate®, and Nuwiq® are designed for patients with bleeding disorders such as Hemophilia A, B, and von Willebrand Disease.
- Immunotherapy: The company provides immunoglobulin therapies, including octagam® and gammanorm®, for treating immune-mediated diseases and deficiencies.
- Critical Care: Products such as albunorm®, octaplas®, and fibryga® are utilized in intensive care and emergency medicine settings.
Market Position
Octapharma is a leading player in the global plasma protein therapeutics market, alongside competitors like CSL Behring LLC and Grifols S.A. The market is projected to grow from $26.25 billion in 2022 to $28.11 billion in 2023, with a compound annual growth rate (CAGR) of 7.1%. By 2027, it is expected to reach $35.84 billion, exhibiting a CAGR of 6.3%.
Recent Developments
- 2024: Octapharma Plasma temporarily halted its plasma donation centers due to unauthorized network activity consistent with a cyber attack, reportedly involving the BlackSuit ransomware. The company informed the Federal Bureau of Investigation and the California Attorney General about the incident.
- 2022: The company launched OctaApp to enhance donor engagement, allowing donors to manage their donations, access history, and receive personalized communication. Within two months of its launch, the app was downloaded by over 100,000 donors.
Strategic Initiatives
Octapharma continues to invest in research and development, operational improvements, and market expansion to drive future growth. In 2024, the company invested over €400 million in initiatives aimed at maximizing the potential of its portfolio and pipeline.
